Effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents

World J Gastroenterol. 2004 Apr 15;10(8):1171-5. doi: 10.3748/wjg.v10.i8.1171.

Abstract

Aim: To investigate the effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents.

Methods: Fifteen samples of autoantibodies against beta(1)-adrenoceptor positive sera of patients with hepatitis virus myocarditis were obtained and IgGs were purified by octanoic acid extraction. Binding of autoantibodies against beta(1)-adrenoceptor to guinea pig cardiac myocytes was examined by immunofluorescence. Using the patch clamp technique, the effects on the action potential and I(Ca-L) of guinea pig cardiac myocytes caused by autoantibodies against beta(1)-adrenoceptor in the absence and presence of metoprolol were investigated. Cell toxicity was examined by observing cell morphology and permeability of cardiac myocytes to trypan blue.

Results: The specific binding of autoantibodies against beta(1)-adrenoceptor to guinea pig cardiomyocytes was observed. Autoantibodies against beta(1)-adrenoceptor diluted at 1:80 prolonged APD(20), APD(50) and APD(90) by 39.2%, 29.1% and 15.2% respectively, and only by 7.2%, 5.3% and 4.1% correspondingly in the presence of 1 micromol/L metoprolol. Autoantibodies against beta(1)-adrenoceptor diluted at 1:80, 1:100 and 1:120 significantly increased the I(Ca-L) peak current amplitude at 0 mV by 55.87+/-4.39%, 46.33+/-5.01% and 29.29+/-4.97% in a concentration-dependent manner. In contrast, after blocking of beta(1)-adrenoceptors (1 micromol/L metoprolol), autoantibodies against beta(1)-adrenoceptor diluted at 1:80 induced a slight increase of I(Ca-L) peak amplitude only by 6.81+/-1.61%. A large number of cardiac myocytes exposed to high concentrations of autoantibodies against beta(1)-adrenoceptor (1:80 and 1:100) were turned into rounded cells highly permeable to trypan blue.

Conclusion: Autoantibodies against beta(1)-adrenoceptor may result in arrhythmias and/or impairment of myocardiums in HVM, which would be mediated by the enhancement of I(Ca-L).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / immunology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Arrhythmias, Cardiac / immunology
  • Autoantibodies / metabolism
  • Autoantibodies / toxicity*
  • Calcium Channels, L-Type / physiology*
  • Guinea Pigs
  • Hepatitis Viruses*
  • In Vitro Techniques
  • Metoprolol / pharmacology
  • Myocarditis / physiopathology*
  • Myocarditis / virology
  • Myocytes, Cardiac / immunology*
  • Myocytes, Cardiac / metabolism
  • Patch-Clamp Techniques
  • Protein Binding / immunology
  • Receptors, Adrenergic, beta-1 / immunology*

Substances

  • Adrenergic beta-Antagonists
  • Autoantibodies
  • Calcium Channels, L-Type
  • Receptors, Adrenergic, beta-1
  • Metoprolol